You are viewing: Japan Hemostats Market analysis
Part of: Hemostats Market (Global)

The Japan Hemostats Market was valued at $38.1 Million in 2025 and projected to reach to $55.4 Million by 2030, representing a compound annual growth rate of CAGR 7.8%. Japan's hemostats market is positioned for sustained growth through 2030, driven by demographic shifts and healthcare modernization.

Japan Hemostats Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Hemostats Market Trends and Insights

  • Japan's aging population and rising surgical volumes are driving demand for advanced hemostatic solutions across hospitals and surgical centers.
  • The market in Japan is benefiting from increased adoption of minimally invasive procedures and technological innovations in hemostatic agents. Japan's healthcare infrastructure and emphasis on surgical excellence position the country as a significant market for hemostats in the Asia Pacific region.
  • Between 2025 and 2030, Japan is expected to see accelerated growth driven by expanding geriatric patient populations requiring surgical interventions.
  • Japan's regulatory environment and strong healthcare spending support the introduction of advanced hemostatic products and sustained market expansion..

Key Market Statistics

  • CAGR (2025-2030) CAGR 7.8%
  • Market Size, 2025 ~USD 38.1 Million
  • Forecast, 2030 ~USD 55.4 Million
  • Country Japan

Japan Hemostats Market Overview

Aging Population Driving Demand :

Japan's rapidly aging demographic is increasing surgical procedures and trauma cases, creating sustained demand for effective hemostatic products in hospitals and surgical centers nationwide.

Minimally Invasive Procedure Adoption :

Growing preference for laparoscopic and endoscopic surgeries in Japan is accelerating adoption of advanced hemostatic solutions that are compatible with minimally invasive techniques.

Strong Market Growth Trajectory :

Japan's hemostats market is expanding at 7.8% CAGR, outpacing the global growth rate of 6.4%, reflecting robust healthcare investment and surgical innovation in the region.

Projected Market Expansion :

Market valuation is expected to grow from $38.1 million in 2025 to $55.4 million by 2030, representing a 45% increase driven by technological advancement and clinical adoption.

Japan Hemostats Market Dynamics

  • The aging population necessitates increased surgical interventions, while hospitals invest in advanced hemostatic technologies to improve patient outcomes and reduce operative complications.
  • Minimally invasive surgical techniques are becoming standard practice, creating demand for specialized hemostatic agents compatible with these procedures. The market will benefit from continued innovation in topical and systemic hemostatic products, alongside strong healthcare infrastructure and reimbursement support.
  • Japanese medical device manufacturers and international players are expanding their portfolios to address specific clinical needs in orthopedic, cardiovascular, and general surgery.
  • Regulatory support and clinical evidence generation will further accelerate market penetration across Japanese healthcare facilities..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • Japan's hemostats market is valued at $38.1 million in 2025 and will reach $55.4 million by 2030 at a 7.8% CAGR.
    • Japan's aging demographic and high surgical volume drive sustained demand for hemostatic solutions.
    • Minimally invasive surgical adoption in Japan accelerates the need for advanced hemostatic agents.
    • Japan's robust healthcare infrastructure and regulatory framework support market growth through 2030.

    Hemostats Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment RECONSTRUCTIVE SURGERY (Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.4% from 2025 to 2030
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 2.93 (2025)
    Revenue Forecast (Billions) ~USD 4 (2030)
    Segments Covered Type, Formulation, Application, End User

    Japan Hemostats Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Collagen-Based Hemostats
    • Combination Hemostats
    • Gelatin-Based Hemostats
    • Other Types
    • Oxidized Regenerated Cellulose-Based Hemostats
    • Thrombin-Based Hemostats

    By Formulation

    • Matrix & Gel Hemostats
    • Powder Hemostats
    • Sheet & Pad Hemostats
    • Sponge Hemostats

    By Application

    • Cardiovascular Surgery
    • General Surgery
    • Gynecological Surgery
    • Neurological Surgery
    • Orthopedic Surgery
    • Other Surgeries
    • Reconstructive Surgery

    By End User

    • Hospitals
    • Specialty Clinics

    JAPAN: HEMOSTATS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS82.388.495102.2110.2119128.6139.27.9
    OTHERS12.813.41414.715.516.217.1185.1
    SPECIALTY CLINICS25.827.429.1313335.237.740.36.7
    TOTAL120.9129.1138.1147.9158.7170.4183.4197.67.4

    Target Audience

    • Medical Device Manufacturers : Manufacturers need Japan-specific market data to develop localized product strategies, identify unmet clinical needs, and plan market entry or expansion in this high-growth healthcare market.
    • Hospital & Surgical Center Procurement : Healthcare facility decision-makers require market intelligence to evaluate hemostats suppliers, benchmark pricing, and optimize procurement strategies aligned with Japan's surgical volume trends.
    • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Japan need detailed market sizing, growth projections, and competitive dynamics to assess portfolio companies and acquisition targets in hemostats.
    • Healthcare Consultants & Advisors : Consulting firms advising clients on Japan market entry or expansion require credible, region-specific data on market size, CAGR, and clinical adoption trends to support strategic recommendations.
    • Regulatory & Clinical Affairs Teams : Regulatory professionals need Japan market context to understand clinical requirements, reimbursement landscape, and competitive positioning when planning product registrations and clinical studies.

    Key Companies in the Japan Hemostats Market

    CompanyHQOwnershipStrongest segments
    CSL LIMITEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BAXTERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    PFIZER INC.United StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BECTON, DICKINSON AND COMPANY (BD)United States
    TELEFLEX INCORPORATEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    MEDTRONIC PLCIrelandPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    STRYKERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    INTEGRA LIFESCIENCESUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    ADVANCED MEDICAL SOLUTIONS GROUP PLCUnited KingdomPublic CompanyGelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts,
    SAMYANG CORPORATIONKorea, Republic ofPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,

    CSL LIMITED

    CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.

    BAXTER

    BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.

    PFIZER INC.

    PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.

    BECTON, DICKINSON AND COMPANY (BD)

    BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.

    TELEFLEX INCORPORATED

    TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.

    MEDTRONIC PLC

    MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.

    STRYKER

    STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.

    INTEGRA LIFESCIENCES

    INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.

    ADVANCED MEDICAL SOLUTIONS GROUP PLC

    ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.

    SAMYANG CORPORATION

    SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.

    Reasons to Buy this Report

    • Japan-Specific Market Sizing : Access precise valuation data for Japan's hemostats market with verified 2025 baseline ($38.1M) and 2030 forecast ($55.4M), enabling accurate financial planning and investment decisions.
    • Demographic Insights & Surgical Trends : Understand how Japan's aging population and rising surgical volumes directly impact hemostats demand, with analysis of procedure types and clinical adoption patterns specific to Japanese healthcare.
    • Competitive Landscape Intelligence : Identify market opportunities and competitive positioning within Japan's hemostats sector, including local manufacturer strategies and international player market entry approaches.
    • Growth Rate Outperformance Data : Leverage Japan's 7.8% CAGR—exceeding global 6.4% growth—to justify market expansion strategies and resource allocation in this high-growth regional market.
    • Minimally Invasive Procedure Adoption Analysis : Gain detailed insights into Japan's shift toward laparoscopic and endoscopic surgeries, identifying product development opportunities and clinical evidence requirements for market success.

    Frequently asked questions

    What is the current size of Japan's hemostats market?

    Japan's hemostats market is valued at $38.1 million in 2025.

    What is the projected market size for hemostats in Japan by 2030?

    Japan's hemostats market is projected to reach $55.4 million by 2030.

    What is the growth rate of Japan's hemostats market?

    Japan's hemostats market is expected to grow at a compound annual growth rate of 7.8% from 2025 to 2030.

    What factors are driving growth in Japan's hemostats market?

    Japan's aging population, rising surgical volumes, increased adoption of minimally invasive procedures, and technological innovations in hemostatic agents are key growth drivers.

    How does Japan's hemostats market compare to other Asia Pacific countries?

    Japan's hemostats market represents a significant portion of the Asia Pacific region due to its advanced healthcare infrastructure, strong surgical capacity, and high healthcare spending.

    RESEARCH METHODOLOGY

    The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

    A breakdown of the primary respondents for the hemostats market is provided below:

    Hemostats Market

    Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

    Note 2: Others include sales, marketing, and product managers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the hemostats market includes the following details.

    The market sizing was undertaken from the global side.

    Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Hemostats Market Size: Top-down Approach

    Hemostats Market

    Data Triangulation

    After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

    Stakeholders

    • Senior Management
    • Finance Department
    • Procurement Department
    • Hospitals
    • Specialty Clinics
    • Trade Associations and Industry Bodies
    • Regulatory Bodies and Government Agencies
    • Business Research & Consulting Service Providers
    • Market Research & Consulting Firms
    • Venture Capitalists and Investors

    Report Objectives

    • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
    • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players in the hemostats market and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

     

    Get the Full Hemostats Market Report

    Full forecast, segment splits, and company analysis for all Hemostats Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status